title: [Clinical experiences and results of application of mitomycin C in trabeculectomy].
abstract: BACKGROUND
  Mitomycin C (MMC) used as an additive agent in glaucoma surgery has been shown to improve the postoperative results of intraocular pressure (IOP), but may also lead to higher incidences of postoperative wound healing disorders and of hypotonia with choroidal detachment. In this retrospective study the levels of IOP, the incidence of complications and changes of the visual acuity (VA) were monitored.
  
  
  METHODS
  A trabeculectomy was performed on 70 eyes (57 patients). During surgery MMC was applied in three different concentrations: 0.1 mg/ml MMC (n = 8), 0.2 mg/ml MMC (n = 53) and 0.4 mg/ml MMC (n = 9) for 2.5 minutes, respectively. Patients were reexamined one day, and at 3 and 12 months after surgery.
  
  
  RESULTS
  IOP was lowered with high statistical significance at all dates of control examination no matter what concentration of MMC had been used. At the time of discharge from hospital the success rate without additional topical glaucoma medication was 96 %, 78 % after 3 months and 68 % after 12 months. With glaucoma medication the success rate was 92 % after 3 months and 85 % after 12 months. Frequent complications were choroidal detachments in 40 % and hypotonia in 21 % of all cases. The VA did not change significantly during the follow-up period.
  
  
  CONCLUSIONS
  This study underlines the efficacy of MMC as an additive agent in glaucoma surgery. However, considerable complications may be expected. Considering the effectiveness and the complication rate a concentration of 0.2 mg/ml MMC should be preferred.
authors.affiliation: Abteilung für Erkrankungen des vorderen Augenabschnitts, Universitätsklinikum Essen. thomas.laube@uni-essen.de
authors.forename: Thomas
authors.initials: T
authors.lastname: Laube
authors.forename: Birgit
authors.initials: B
authors.lastname: Ritters
authors.forename: Michael
authors.initials: M
authors.lastname: Selbach
authors.forename: Tobias
authors.initials: T
authors.lastname: Hudde
mesh_terms: D000368:Aged; D015862:Choroid Diseases / Q000139:chemically induced; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D005901:Glaucoma / Q000601:surgery*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D007910:Lenses, Intraocular; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage* / Q000009:adverse effects; D011183:Postoperative Complications / Q000139:chemically induced / Q000188:drug therapy; D012086:Reoperation; D012189:Retrospective Studies; D012307:Risk Factors; D055502:Secondary Prevention; D014130:Trabeculectomy; D014792:Visual Acuity / Q000187:drug effects*; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D016685:Mitomycin